Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Viventia cancer combination therapy shows effectiveness
Viventia is currently enrolling patients in its phase III clinical trial that is expected to complete accrual by the end of 2007. The combination of Proxinium with cisplatin,
Viventia is currently enrolling patients in its phase III clinical trial that is expected to complete accrual by the end of 2007. The combination of Proxinium with cisplatin,
Under the terms of the royalty bearing agreements, Carrington will supply its raw material, acemannan hydrogel, to Primus for use in topical prescription products. In exchange for guaranteed
According to the study, GX15-070 demonstrated potent single agent activity against acute lymphoblastic leukemia (ALL) blast cells, and also enhanced chemosensitivity and was synergistic with cytotoxic drugs. GX15-070
Sales rose to CHF11.4 billion ($9.42 billion), between January and March. As a result Roche anticipates continued strong growth for 2007. Overall the pharmaceuticals division grew by 20%
The phase Ib trial was designed to study the safety, tolerability, pharmacokinetics and pharmacodynamics of PRX-07034, a 5-HT6 antagonist, administered orally once-daily for 28 days in a population
The company said it has sought scientific advice on final aspects of the trial design from regulatory authorities in Europe and the US and expects to initiate patient
The Japanese Ministry of Health, Labor and Welfare has granted this approval following a recommendation, made in July 2005 by the Investigational Committee for Usage of Unapproved Drugs,
The preclinical study conducted at the University of California Irvine, with US bioscience company Martek’s support, used genetically modified mice. It is the first study to show that
The aims of the current phase I/II trial are to determine the maximum tolerated dose of the drug candidate BZL101 and tumor response in women with late stage
Biosite’s board of directors will review and evaluate the new information provided by Inverness. As previously reported, a subsidiary of Beckman Coulter has commenced a cash tender offer